Overview

Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
1. Evaluate the efficacy and safety of taking thalidomide tablets once daily in the treatment of active ankylosing spondylitis. 2. To explore dose-effect relationships of taking thalidomide tablets once daily in the treatment of active ankylosing spondylitis, as well as selecting the appropriate dose for the further larger scale clinical trials.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Pharmaceuticals Holding Co., Ltd
Treatments:
Thalidomide
Tolnaftate